Literature DB >> 11975693

Differential tramadol and O-desmethyl metabolite levels in brain vs. plasma of mice and rats administered tramadol hydrochloride orally.

Q Tao1, D J Stone, M R Borenstein, E E Codd, T P Coogan, D Desai-Krieger, S Liao, R B Raffa.   

Abstract

OBJECTIVE: To investigate a possible differential brain uptake of tramadol vs. its major metabolite (O-desmethyl tramadol; M1) in mice and rats.
METHODS: An extraction and measurement technique (gas chromatograph equipped with a nitrogen phosphorus detector) was used to measure plasma and brain levels of tramadol and M1 at intervals 10-300 min after oral dosing of tramadol hydrochloride to mice and rats.
RESULTS: For all doses of tramadol administered (5, 10, 20, or 40 mg/kg), tramadol and M1 plasma levels were greatest 10 min after dosing: in mice, peak tramadol plasma levels were 47.75-736.72 ng/mL and peak M1 levels were 75.30-1084.92 ng/mL; in rats, peak tramadol plasma levels were 185.03-455.81 ng/mL and peak M1 levels were 106.74-455.70 ng/mL. Tramadol brain levels were also greatest 10 min after dosing. In mice, peak tramadol brain levels were 226.42-1847.46 ng/g. Peak M1 levels (72.17-572.97 ng/g) occurred 20-60 min after dosing. In rats, peak tramadol brain levels were 258.50-1777.37 ng/g and peak M1 levels were 80.35-289.60 ng/g. In mice, the ratio of tramadol/M1 in plasma was 0.5-1.0 throughout the measurements, whereas the ratio in brain was about 10 at 10 min and about 2 from 20 to 50 min. In rats, the ratio of tramadol/M1 in plasma was 0.5-1.5, whereas the ratio in brain was about 15 at 10 min and about 4-7 thereafter.
CONCLUSION: In mice and rats, there appears to be preferential brain vs. plasma distribution of tramadol over M1.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11975693     DOI: 10.1046/j.1365-2710.2002.00384.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  6 in total

1.  Liver and kidney toxicity in chronic use of opioids: an experimental long term treatment model.

Authors:  Sebnem Atici; Ismail Cinel; Leyla Cinel; Nurcan Doruk; Gulcin Eskandari; Ugur Oral
Journal:  J Biosci       Date:  2005-03       Impact factor: 1.826

Review 2.  Clinical pharmacology of tramadol.

Authors:  Stefan Grond; Armin Sablotzki
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials.

Authors:  John A Zebala; Shawn L Searle; Lynn R Webster; Matt S Johnson; Aaron D Schuler; Dean Y Maeda; Stuart J Kahn
Journal:  J Pain       Date:  2019-04-18       Impact factor: 5.820

4.  The analgesic interaction of tramadol and morphine in rats: An isobolographic study.

Authors:  Hesam Savadkoohi; Nasser Vesal
Journal:  Vet Res Forum       Date:  2019-03-15       Impact factor: 1.054

5.  Serotonin and Norepinephrine Transporter Occupancy of Tramadol in Nonhuman Primate Using Positron Emission Tomography.

Authors:  Ryosuke Arakawa; Akihiro Takano; Christer Halldin
Journal:  Int J Neuropsychopharmacol       Date:  2019-01-01       Impact factor: 5.176

6.  Short Onset and Enhanced Analgesia Following Nasal Administration of Non-Controlled Drugs in Nanovesicular Systems.

Authors:  Elka Touitou; Hiba Natsheh; Shatha Boukeileh; Rania Awad
Journal:  Pharmaceutics       Date:  2021-06-28       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.